title: Fresh-frozen plasma as a source of exogenous insulin-like growth factor-I in the extremely preterm infant.
abstract: BACKGROUND
  Preterm birth is followed by a decrease in circulatory levels of IGF-I and IGF binding protein (IGFBP)-3, proteins with important neurogenic and angiogenic properties.
  
  
  OBJECTIVE
  Our objective was to evaluate the effects of iv administration of fresh-frozen plasma (FFP) from adult donors on circulatory levels of IGF-I and IGFBP-3 in extremely preterm infants.
  
  
  METHODS
  A prospective cohort study was performed in 20 extremely preterm infants [mean (SD) gestational age 25.3 (1.3) wk] with clinical requirement of FFP during the first postnatal week. Sampling was performed before initiation of transfusion, directly after, and at 6, 12, 24, and 48 h after completed FFP transfusion.
  
  
  METHODS
  Concentrations of IGF-I and IGFBP-3 before and after transfusion of FFP were determined.
  
  
  RESULTS
  FFP with a mean (SD) volume of 11 ml/kg (3.1) was administered at a median postnatal age of 2 d (range 1-7). Mean (SD) IGF-I and IGFBP-3 concentrations in administered FFP were 130 (39) and 2840 microg/liter (615), respectively. Immediately after FFP transfusion, mean (SD) concentrations of IGF-I increased by 133% from 11 (6.4) to 25 microg/liter (9.3) (P < 0.001) and IGFBP-3 by 61% from 815 (451) to 1311 microg/liter (508) (P < 0.001). Concentrations of IGF-I and IGFBP-3 remained higher at 6 (P < 0.001, P = 0.009) and 12 h (P = 0.017, P = 0.018), respectively, as compared with concentrations before FFP transfusion. Typical half-life of administrated IGF-I was 3.4 h for a 1-kg infant.
  
  
  CONCLUSIONS
  Transfusion of FFP to extremely preterm infants during the first postnatal week elevates levels of IGF-I and IGFBP-3.
authors.affiliation: Division of Pediatrics, Department of Clinical Sciences Lund, Lund University Hospital, 221 85 Lund, Sweden. ingrid.pupp@skane.se
authors.forename: Ingrid
authors.initials: I
authors.lastname: Hansen-Pupp
authors.forename: Eva
authors.initials: E
authors.lastname: Engström
authors.forename: Aimon
authors.initials: A
authors.lastname: Niklasson
authors.forename: Ann-Cathrine
authors.initials: AC
authors.lastname: Berg
authors.forename: Vineta
authors.initials: V
authors.lastname: Fellman
authors.forename: Chatarina
authors.initials: C
authors.lastname: Löfqvist
authors.forename: Ann
authors.initials: A
authors.lastname: Hellström
authors.forename: David
authors.initials: D
authors.lastname: Ley
mesh_terms: D001786:Blood Glucose / Q000032:analysis; D001803:Blood Transfusion / Q000379:methods; D003131:Combined Modality Therapy; D005865:Gestational Age; D006801:Humans; D052577:Infant, Extremely Low Birth Weight / Q000097:blood; D007231:Infant, Newborn; D018972:Insulin-Like Growth Factor Binding Protein 3; D018969:Insulin-Like Growth Factor Binding Proteins / Q000032:analysis / Q000097:blood; D007334:Insulin-Like Growth Factor I / Q000008:administration & dosage* / Q000032:analysis / Q000172:deficiency; D010288:Parenteral Nutrition; D010949:Plasma / Q000737:chemistry / Q000502:physiology; D047928:Premature Birth / Q000097:blood / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; C515497:IGFBP3 protein, human; D018972:Insulin-Like Growth Factor Binding Protein 3; D018969:Insulin-Like Growth Factor Binding Proteins; D007334:Insulin-Like Growth Factor I